文献速递骨质疏松与代谢性骨病

欧洲生物学变异研究:I型胶原β-CTX、PINP、骨钙素、完整FGF23及uc-MGP的个体内与个体间生物学变异估计

European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and th
PubMed 文献 · Osteoporos Int · 2020-04-08

CVI估计分别为β-CTX 15.1%、PINP 8.8%、OC 8.9%、iFGF23 13.9%、uCuP-MGP 6.9%,性别对CVI无影响,有助于改进代谢性骨病患者的随访。

要点

  • 提供了β-CTX、PINP、OC、iFGF23和uCuP-MGP的CVI估计及95%CI。
  • 性别对CVI估计无影响。
  • 结果可用于计算参考变化值(RCV)以判断随访差异的生物学意义。

核心结论

  • EuBIVAS提供了骨代谢标志物更新的生物学变异估计,包括此前未发表的iFGF23,有助于改进代谢性骨病治疗患者的随访。

研究设计与样本

  • 结果经离群值和方差齐性分析后,采用CV-ANOVA获得生物学变异估计。

主要发现

  • CVI估计(95%CI)为:β-CTX 15.1%(14.4-16.0%)、PINP 8.8%(8.4-9.3%)、OC 8.9%(8.5-9.4%)、iFGF23 13.9%(13.2-14.7%)、uCuP-MGP 6.9%(6.1-7.3%)。
  • 未发现性别对CVI估计有影响。

关键数值与推荐

  • β-CTX的CVI为15.1%(95%CI 14.4-16.0%)。
  • PINP的CVI为8.8%(95%CI 8.4-9.3%)。
  • OC的CVI为8.9%(95%CI 8.5-9.4%)。
  • iFGF23的CVI为13.9%(95%CI 13.2-14.7%)。
  • uCuP-MGP的CVI为6.9%(95%CI 6.1-7.3%)。

临床怎么用

  • 利用本研究的CVI估计计算参考变化值(RCV)或最小显著变化,以判断患者两次连续测量间的差异是否具有生物学意义。
  • 在代谢性骨病治疗随访中,可参考这些生物学变异数据优化骨代谢标志物的监测解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. INTRODUCTION: Within-subject (CVI) and between-subject (CVG) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). METHODS: In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. RESULTS: We found no effect of gender upon the CVI estimates. The following CVI estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4-16.0%), PINP 8.8% (8.4-9.3%), OC 8.9% (8.5-9.4%), iFGF23 13.9% (13.2-14.7%), and uCuP-MGP 6.9% (6.1-7.3%). CONCLUSIONS: The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cavalier E, Lukas P, Bottani M, et al. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporos Int. 2020. PMID: 32270253. doi:10.1007/s00198-020-05362-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。